An oral form of Novo Nordisk's weight loss drug gets the US regulator's nod, adding a needle-free option. Details on what changes for patients are at the link.
Recap by typeshit. Full story at BusinessWorld Online.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Revenue rose to $13.2M from $7.6M a year earlier while net loss widened to $61.9M, with the company also pointing to progress in its obesity pipeline.
The Nature Cardiovascular Research team found the protection held even when the peptides were given at reperfusion. So far the results come only from mice and cultured cells.
Loading…